In the News

08 Feb '2018

Medical Sciences 2018, 6(1), 9

At the European Gynecological Oncology Congress (ESGO) 2017, held in Vienna, a symposium on immunotherapy took place: A New Strategy for the Treatment of Cervical Cancer, sponsored by Advaxis, Inc.  

Dr. Christian Marth, the chair of the symposium, and Dr. Sharad Ghamande, a Gynecological Oncologist coordinating a clinical study of the immunotherapy drug axalimogene filolisbac, shared with us their views about the current state of immunotherapy in cervical cancer.

23 Jan '2018

nternational Journal of Radiation Oncology

ADXS11-0011 Lm-LLO is a live attenuated Listeria monocytogenes (Lm) bacterium bioengineered to secrete the HPV-16 E7 protein fused with a truncated fragment of listeriolysin O (tLLO) that preferentially infects antigen-presenting cells. Exposure to ADXS11-001 may stimulate T-cells to target HPV-transformed cells. The objective of this study was to obtain safety and preliminary efficacy data of the combination of ADXS11-001 with mitomycin, FU and intensity modulated radiation